Merus/$MRUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Ticker

$MRUS
Sector
Primary listing

Employees

291

Merus Metrics

BasicAdvanced
$7.1B
-
-$5.57
1.19
-

What the Analysts think about Merus

Analyst ratings (Buy, Hold, Sell) for Merus stock.

Bulls say / Bears say

The U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in combination with pembrolizumab for first-line PD-L1+ r/m head and neck squamous cell carcinoma in February 2025, expediting its development path (Nasdaq turn9search0)
Merus completed a public offering in June 2025, raising $345 million gross and resulting in $892 million in cash, cash equivalents and marketable securities as of June 30, 2025, sufficient to fund operations into 2028 (Merus Q2 2025 Press Release turn8view0)
Interim data from the phase 2 trial of petosemtamab with pembrolizumab presented at ASCO 2025 demonstrated a 63% response rate among 43 evaluable patients, underscoring robust clinical efficacy in first-line HNSCC (Merus Q2 2025 Press Release turn8view0)
Research and development expenses surged by $44.8 million in Q2 2025 versus Q2 2024, reflecting escalating cash burn that could strain Merus’s cash runway absent product revenues (Merus Q2 2025 Press Release turn8view0)
Collaboration revenue growth was a modest $1.5 million in Q2 2025 year-over-year, underscoring Merus’s continued reliance on partnership deals rather than product sales for income (Merus Q2 2025 Press Release turn8view0)
Merus’s accumulated deficit ballooned to $1.223 billion as of June 30, 2025, highlighting prolonged unprofitability and raising concerns about potential future equity dilution (Merus Q2 2025 Press Release turn8view0)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Merus Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merus Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRUS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs